Navigation Links
Eon Labs Pays U.S. $3.5 Million to Settle Allegations of Submitting False Claims to Medicaid
Date:2/22/2010

Sandoz Subsidiary Allegedly Submitted Claims for Drug Determined to be Ineligible by FDA

WASHINGTON, Feb. 22 /PRNewswire-USNewswire/ -- Eon Labs Inc. has agreed to pay the United States $3.5 million to resolve False Claims Act allegations relating to the company's drug Nitroglycerin Sustained Release (SR) capsules, the Justice Department announced today. Eon Labs is a subsidiary of Sando  Inc., which is in turn a subsidiary of Novartis AG.

In April 1999, the Food & Drug Administration (FDA) determined that Nitroglycerin SR lacked substantial evidence of effectiveness and published a notice proposing to withdraw approval of the product. The government contends that, after the FDA notice, Nitroglycerin SR no longer was legally eligible for reimbursement by government health care programs such as Medicaid.

The government further alleges that, from April 1999, and continuing through September 2008, Eon submitted false quarterly reports to the government that misrepresented Nitroglycerin SR's regulatory status and failed to advise that Nitroglycerin SR no longer qualified for Medicaid coverage. As a result, the government contends, Eon knowingly caused false Medicaid claims to be submitted for Nitroglycerin SR.

"We expect manufacturers to be truthful about the regulatory status of their drugs, and we will pursue those companies that submit false information to obtain payment for unapproved drugs that are less than effective or on the market illegally," said Tony West, Assistant Attorney General for the Civil Division.

The settlement resolves allegations against Eon in a multi-defendant whistleblower action entitled United States ex rel. Conrad v. Eon Labs, Inc., et al. The False Claims Act allows for private persons to file a qui tam or whistleblower suit on behalf of the government. If the government is successful in resolving or litigating its claims, the whistleblower may receive a share of the recovery. Under this settlement, the whistleblower will receive approximately $525,000.

"This is the first False Claims Act agreement with a drug company that sought to charge the government for less than effective drugs, and it shows that the Department of Justice will pursue those who market such drugs and expect the government to pay for them," said Carmen Ortiz, U.S. Attorney for the District of Massachusetts.

This settlement is part of the government's emphasis on combating health care fraud. One of the powerful tools in that effort is the False Claims Act, which the Justice Department has used to recover approximately $2.2 billion since January 2009 in cases involving fraud against federal health care programs. The Justice Department's total recoveries in False Claims Act cases since January 2009 have topped $3 billion.

This case was investigated by the Justice Department's Civil Division, the U.S. Attorney's Office of the District of Massachusetts and the Office of Inspector General of the Department of Health and Human Services.

SOURCE U.S. Department of Justice

Back to top

RELATED LINKS
http://www.justice.gov

'/>"/>

SOURCE U.S. Department of Justice
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. Atritech Announces Completion of a $22 Million Equity Financing
3. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
4. EntreMed Raises $20 Million to Support Clinical Development Program
5. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
6. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
7. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
8. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
9. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
10. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
11. 38.7 Million People Break Guinness World Record for Stand Up Speak Out on International Day for the Eradication of Poverty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... , June 6, 2017  Diplomat Specialty Infusion Group, a ... compounding environment to its Iowa location. ... Urbandale now features an ISO 7 cleanroom—the standard needed ... environment with a low level of pollutants. ... IV nutrition consumers and better serve our Iowa ...
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
(Date:5/26/2017)... 26, 2017  Endo International plc (NASDAQ: ENDP ... CEO, will represent the Company in a fireside chat at ... Tuesday, June 13, 2017 at 10:40 a.m. PT / 1:40 ... in Rancho Palos Verdes, CA. ... will be available on the Company,s website at http://www.endo.com/investors/overview ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... 28, 2017 , ... Eating disorders have the highest mortality rate of any ... person dies as a direct result from an eating disorder in the U.S. As ... The iaedp Foundation meets this challenge by offering what has become the leading certification ...
(Date:6/28/2017)... , ... June 28, 2017 , ... Park Systems ... AFM Luncheon for all SEMICONWest attendees and Park customers on July 11, ... talks from Dr. Sang-il Park, Chairman & CEO of Park Systems, and Prof. ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... financial consultations to communities in northern Virginia and DC, is announcing a cooperative ... for patients with Alzheimer’s and other disorders that lead to memory impairment. , ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands that ... they can trust the sponsor to pay them correctly and on time. As the ... establish payment strategies that encourage sites to work on their studies. , At a ...
(Date:6/27/2017)... ... June 27, 2017 , ... Building on the ... Louisiana became the sixth state to pass legislation which ensures that children can ... signature, Louisiana joins the states of Alabama, Arizona, Florida, Utah and Washington who ...
Breaking Medicine News(10 mins):